Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Natural killer group 2D receptor ligands (NKG2DLs) are a family of cell surface proteins recognized by the NKG2D receptor, an activating immunoreceptor found on natural killer (NK) cells and certain T cell subsets. These ligands are typically upregulated in response to cellular stress, such as infection, DNA damage, or malignant transformation. In humans, the main NKG2D ligands include MICA, MICB, and ULBP1–ULBP6. Binding of these ligands to the NKG2D receptor activates NK cells and some T cell subsets, triggering cytotoxicity against target cells and cytokine secretion. They are a target for cancer immunotherapy.
NKG2DLs bind to the NKG2D receptor on NK cells and some T cell subsets, triggering activation through DAP10 (humans) and DAP10/DAP12 (mice) signaling pathways. This leads to cytotoxicity and cytokine production.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Natural Killer Group 2D Receptor Ligand (NKG2DL).